Institution
University of São Paulo
Education•São Paulo, Brazil•
About: University of São Paulo is a education organization based out in São Paulo, Brazil. It is known for research contribution in the topics: Population & Context (language use). The organization has 136513 authors who have published 272320 publications receiving 5127869 citations. The organization is also known as: USP & Universidade de São Paulo.
Topics: Population, Context (language use), Medicine, Health care, Immune system
Papers published on a yearly basis
Papers
More filters
Memorial Sloan Kettering Cancer Center1, Broad Institute2, Heidelberg University3, University of São Paulo4, University of California, Santa Cruz5, Harvard University6, Institute for Systems Biology7, University of Texas MD Anderson Cancer Center8, Case Western Reserve University9, Henry Ford Health System10, Duke University11, Emory University12, University of California, San Francisco13, Cedars-Sinai Medical Center14, St. Joseph's Hospital and Medical Center15, University of Florida16, Thomas Jefferson University17, University of Toronto18, Christiana Care Health System19, Mayo Clinic20, Penrose Hospital21, University of Southern California22, University of North Carolina at Chapel Hill23, Baylor College of Medicine24, University of British Columbia25, Oregon Health & Science University26, Washington University in St. Louis27
TL;DR: Correlative analyses confirm that the survival advantage of the proneural subtype is conferred by the G-CIMP phenotype, and MGMT DNA methylation may be a predictive biomarker for treatment response only in classical subtype GBM.
3,593 citations
University of Glasgow1, Brigham and Women's Hospital2, Yale University3, University of Copenhagen4, University of Missouri–Kansas City5, National University of Cordoba6, Wrocław Medical University7, Harvard University8, University of Minnesota9, Charles University in Prague10, Saarland University11, Taipei Veterans General Hospital12, National Yang-Ming University13, Slovak Medical University14, Fudan University15, Libin Cardiovascular Institute of Alberta16, University of Calgary17, Sofia Medical University18, University of Gothenburg19, Semmelweis University20, University of São Paulo21, Montreal Heart Institute22, University of Toronto23, Uppsala University24, University of Wisconsin-Madison25, AstraZeneca26
TL;DR: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than amongThose who received placebo, regardless of the presence or absence of diabetes.
Abstract: Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-ind...
3,541 citations
Howard Hughes Medical Institute1, Johns Hopkins University2, Swim Across America3, Boston University4, University of Turin5, Life Technologies6, Indiana University Health7, Indiana University8, Ludwig Institute for Cancer Research9, University of Pennsylvania10, University of Ulsan11, University of São Paulo12, Amgen13, Karolinska Institutet14, University of Colorado Boulder15, Memorial Sloan Kettering Cancer Center16, Indiana University – Purdue University Indianapolis17
TL;DR: The ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types was evaluated and suggested that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes.
Abstract: The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain reaction-based technologies to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types. We found that ctDNA was detectable in >75% of patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal, prostate, or thyroid cancers. In patients with localized tumors, ctDNA was detected in 73, 57, 48, and 50% of patients with colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma, respectively. ctDNA was often present in patients without detectable circulating tumor cells, suggesting that these two biomarkers are distinct entities. In a separate panel of 206 patients with metastatic colorectal cancers, we showed that the sensitivity of ctDNA for detection of clinically relevant KRAS gene mutations was 87.2% and its specificity was 99.2%. Finally, we assessed whether ctDNA could provide clues into the mechanisms underlying resistance to epidermal growth factor receptor blockade in 24 patients who objectively responded to therapy but subsequently relapsed. Twenty-three (96%) of these patients developed one or more mutations in genes involved in the mitogen-activated protein kinase pathway. Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer.
3,533 citations
TL;DR: In this paper, the authors discuss the relationship between political regimes and economic growth in the United States and discuss the dynamics of political regimes, economic growth, political instability, and population.
Abstract: Introduction 1. Democracies and dictatorships 2. Dynamic of political regimes 3. Political regimes and economic growth 4. Political instability and economic growth 5. Political regimes and population Conclusion.
3,391 citations
TL;DR: The methodology and guidance for the conduct of systematic scoping reviews outlined below was developed by members of the JoAnna Briggs Institute and members of five Joanna Briggs Collaborating Centres.
Abstract: Reviews of primary research are becoming more common as evidence-based practice gains recognition as the benchmark for care, and the number of, and access to, primary research sources has grown. One of the newer review types is the 'scoping review'. In general, scoping reviews are commonly used for 'reconnaissance' - to clarify working definitions and conceptual boundaries of a topic or field. Scoping reviews are therefore particularly useful when a body of literature has not yet been comprehensively reviewed, or exhibits a complex or heterogeneous nature not amenable to a more precise systematic review of the evidence. While scoping reviews may be conducted to determine the value and probable scope of a full systematic review, they may also be undertaken as exercises in and of themselves to summarize and disseminate research findings, to identify research gaps, and to make recommendations for the future research. This article briefly introduces the reader to scoping reviews, how they are different to systematic reviews, and why they might be conducted. The methodology and guidance for the conduct of systematic scoping reviews outlined below was developed by members of the Joanna Briggs Institute and members of five Joanna Briggs Collaborating Centres.
3,390 citations
Authors
Showing all 138091 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| George M. Whitesides | 240 | 1739 | 269833 |
| Peter Libby | 211 | 932 | 182724 |
| Robert C. Nichol | 187 | 851 | 162994 |
| Paul M. Thompson | 183 | 2271 | 146736 |
| Terrie E. Moffitt | 182 | 594 | 150609 |
| Douglas R. Green | 182 | 661 | 145944 |
| Richard B. Lipton | 176 | 2110 | 140776 |
| Robin M. Murray | 171 | 1539 | 116362 |
| George P. Chrousos | 169 | 1612 | 120752 |
| David A. Bennett | 167 | 1142 | 109844 |
| Barry M. Popkin | 157 | 751 | 90453 |
| David H. Adams | 155 | 1613 | 117783 |
| Joao Seixas | 153 | 1538 | 115070 |
| Matthias Egger | 152 | 901 | 184176 |
| Ichiro Kawachi | 149 | 1216 | 90282 |